In the anti-PD-L1 monotherapy group, one tumor did not grow out, and if this outlier is removed, the combination therapy also performed significantly better than anti-PD-L1 alone (day 23/26: p = 0.0281). The gene discussed is CD274; the disease is neoplasm.